Mylan Launches First Generic Version of Zovirax® Ointment

          Mylan Launches First Generic Version of Zovirax® Ointment

PR Newswire

PITTSBURGH, April 3, 2013

PITTSBURGH, April 3, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today
announced that its subsidiary Mylan Pharmaceuticals has received final
approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated
New Drug Application (ANDA) for Acyclovir Ointment USP, 5%. This product is
the first generic version of Valeant International's Zovirax^® Ointment, which
is indicated in the management of initial genital herpes and in limited
non-life-threatening mucocutaneous herpes simplex virus infections in
immunocompromised patients.

Acyclovir Ointment USP, 5% had U.S. sales of approximately $230 million for
the 12 months ending Dec. 31, 2012, according to IMS Health. Mylan is shipping
this product immediately.

Currently, Mylan has 178 ANDAs pending FDA approval representing $78.4 billion
in annual sales, according to IMS Health. Thirty-five of these pending ANDAs
are potential first-to-file opportunities, representing $20.3 billion in
annual brand sales, for the 12 months ending June 30, 2012, according to IMS
Health.

Mylan is a global pharmaceutical company committed to setting new standards in
health care. Working together around the world to provide 7 billion people
access to high quality medicine, we innovate to satisfy unmet needs; make
reliability and service excellence a habit; do what's right, not what's easy;
and impact the future through passionate global leadership. We offer a growing
portfolio of approximately 1,100 generic pharmaceuticals and several brand
medications. In addition, we offer a wide range of antiretroviral therapies,
upon which approximately 40% of HIV/AIDS patients in developing countries
depend. We also operate one of the largest active pharmaceutical ingredient
manufacturers and currently market products in approximately 140 countries and
territories. Our workforce of more than 20,000 people is dedicated to
improving the customer experience and increasing pharmaceutical access to
consumers around the world. But don't take our word for it. See for yourself.
See inside. mylan.com

SOURCE Mylan Inc.

Website: http://www.mylan.com
Contact: Nina Devlin (Media), 724.514.1968, or Kris King (Investors),
724.514.1813
 
Press spacebar to pause and continue. Press esc to stop.